Edwards Lifesciences Corporation (EW) Q4 2012 Earnings Results

Edwards Lifesciences Beats on EPS, Stock Down 0.37%

Edwards Lifesciences reported a better-than-expected EPS, which indicates strong profitability. However, the stock fell slightly by 0.37%, possibly due to the lack of revenue data and forward guidance. Investors may be cautious given the current market conditions and the absence of specific future projections from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.90	N/A	+16.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook for the company's core products. However, they acknowledged ongoing market pressures.

Management highlighted strong performance in key product areas.

They expressed confidence in future growth despite market challenges.

Edwards Lifesciences Beats on EPS, Stock Down 0.37%

Key numbers

Management commentary

Edwards Lifesciences Corporation

More earnings this week

Edwards Lifesciences Beats on EPS, Stock Down 0.37%

Key numbers

Management commentary